The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Drug With a (Re)Purpose: Thalidomide, once infamous for its deleterious effects on fetal development, has re-emerged as a drug of great interest because of its beneficial immunomodulatory effects. A derivative drug called lenalidomide significantly extends the survival of patients with multiple myeloma, but the molecular mechanisms underlying its efficacy remain unclear (see the Perspective by Stewart ). Building on a previous observation that thalidomide binds to cereblon, a ubiquitin ligase, Lu et al. (p. 305 , published online 28 November) and Krönke et al. (p. 301 , published online 28 November) show that in the presence of lenalidomide, cereblon selectively targets two B cell transcription factors (Ikaros family members, IKZF1 and IKZF3) for degradation. In myeloma cell lines and patient cells, down-regulation of IKZF1 and IKZF3 was necessary and sufficient for the drug's anticancer activity. Thus, lenalidomide may act, at least in part, by “grepurposing” a ubiquitin ligase.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogues recruit zinc-finger transcription factors and other targets to CRBN8–11, the substrate receptor of the cullin-RING E3 ubiquitin ligase CUL4A/B-RBX1-DDB1-CRBN (CRL4CRBN)12.”
From The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K (2020) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IMiDs bind to cereblon and activate cereblon E3 ligase activity, resulting in the rapid ubiquitination and degradation of two specific B cell transcription factors, Ikaros family zinc finger proteins Ikaros (IKZF 1) and Aiolos (IKZF3).77–79”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [79]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The small molecules thalidomide, lenalidomide, and pomalidomide induce the ubiquitination and proteasomal degradation of the transcription factors Ikaros (IKZF1) and Aiolos (IKZF3) by recruiting a Cys2-His2 (C2H2) zinc finger domain to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase.”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thalidomide analogs bind Cereblon (CRBN), the substrate receptor of the CUL4-RBX1-DDB1-CRBN (CRL4CRBN) E3 ubiquitin ligase and alter its substrate selectivity to recruit, ubiquitinate and degrade seemingly unrelated proteins including Ikaros (IKZF1), Aiolos (IKZF3), Casein kinase 1 alpha (CK1α) and GSPT1 (2–7).”
From Defining the human C2H2 zinc finger degrome targeted by thalidomide analogs through CRBN (2018) · cites this paper as [2]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These compounds, collectively known as immunomodulatory drugs (IMiDs), can promote the degradation of a host of cellular proteins by extending the subpar interfaces they form with CRBN, the substrate receptor of the CUL4-RBX1-DDB1 (CRL4) ubiquitin ligase complex9–20.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [11]
Experimental — accuracy not yet measured
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multiplex Genome Engineering Using CRISPR/Cas Systems
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., et al. (2013) · Science · doi:10.1126/science.1231143 · Cited by 15,339
RNA-Guided Human Genome Engineering via Cas9
Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., & Church, G. M. (2013) · Science · doi:10.1126/science.1232033 · Cited by 9,210
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961
Self-citationRaje, N., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,163
Identification of a Primary Target of Thalidomide Teratogenicity
Ito, T., Ando, H., Suzuki, T., Ogura, T., Hotta, K., Imamura, Y., Yamaguchi, Y., & Handa, H. (2010) · Science · doi:10.1126/science.1177319 · Cited by 2,136
An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
Soucy, T. A., Smith, P. G., Milhollen, M. A., Berger, A. J., Gavin, J. M., Adhikari, S., Brownell, J. E., Burke, K. E., Cardin, D. P., Critchley, S., et al. (2009) · Nature · doi:10.1038/nature07884 · Cited by 1,990
Lopez-Girona, A., Mendy, D., Ito, T., Miller, K., Gandhi, A. K., Kang, J., Karasawa, S., Carmel, G., Jackson, P., Abbasian, M., et al. (2012) · Leukemia · doi:10.1038/leu.2012.119 · Cited by 814
Mutation of FOXL2 in Granulosa-Cell Tumors of the Ovary
Shah, S. P., Köbel, M., Senz, J., Morin, R. D., Clarke, B. A., Wiegand, K. C., Leung, G., Zayed, A., Mehl, E., Kalloger, S. E., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902542 · Cited by 768
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Self-citationCereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide
Zhu, Y. X., Braggio, E., Shi, C.-X., Bruins, L. A., Schmidt, J. E., Van Wier, S., Chang, X.-B., Bjorklund, C. C., Fonseca, R., Bergsagel, P. L., et al. (2011) · Blood · doi:10.1182/blood-2011-05-356063 · Cited by 607
Cited by
Items 301–400 of 1,006
Poczta, A., Rogalska, A., & Marczak, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091841 · Cited by 88
CRISPR Screen Reveals BRD2/4 Molecular Glue-like Degrader via Recruitment of DCAF16
Shergalis, A. G., Marin, V. L., Rhee, D. Y., Senaweera, S., McCloud, R. L., Ronau, J. A., Hutchins, C. W., McLoughlin, S., Woller, K. R., Warder, S. E., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00747 · Cited by 73
Schreiber, S. L. (2019) · Israel Journal of Chemistry · doi:10.1002/ijch.201800113 · Cited by 77
Ubiquitin ligases in cancer: Functions and clinical potentials
Duan, S., & Pagano, M. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.04.008 · Cited by 85
UBE2G1 governs the destruction of cereblon neomorphic substrates
Lu, G., Weng, S., Matyskiela, M., Zheng, X., Fang, W., Wood, S., Surka, C., Mizukoshi, R., Lu, C.-C., Mendy, D., et al. (2018) · eLife · doi:10.7554/elife.40958 · Cited by 78
Self-citationPIKES Analysis Reveals Response to Degraders and Key Regulatory Mechanisms of the CRL4 Network
Reichermeier, K. M., Straube, R., Reitsma, J. M., Sweredoski, M. J., Rose, C. M., Moradian, A., den Besten, W., Hinkle, T., Verschueren, E., Petzold, G., et al. (2020) · Molecular Cell · doi:10.1016/j.molcel.2019.12.013 · Cited by 78
Schafer, P. H., Ye, Y., Wu, L., Kosek, J., Ringheim, G., Yang, Z., Liu, L., Thomas, M., Palmisano, M., & Chopra, R. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212916 · Cited by 78
Recent advances in the molecular mechanism of thalidomide teratogenicity
Gao, S., Wang, S., Fan, R., & Hu, J. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110114 · Cited by 78
Wang, S., Zhao, L.-J., Zheng, Y., Shen, D., Miao, E.-F., Qiao, X.-P., Zhao, L., Liu, Y. M., Huang, R., Yu, B., et al. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.10.021 · Cited by 78
The next-generation KRAS inhibitors…What comes after sotorasib and adagrasib?
Oya, Y., Imaizumi, K., & Mitsudomi, T. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107886 · Cited by 65
Computer-Aided Drug Discovery for Undruggable Targets
Sun, Q., Wang, H., Xie, J., Wang, L., Mu, J., Li, J., Ren, Y., & Lai, L. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00969 · Cited by 82
Hansen, J. D., Condroski, K., Correa, M., Muller, G., Man, H.-W., Ruchelman, A., Zhang, W., Vocanson, F., Crea, T., Liu, W., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01911 · Cited by 75
Self-citationHumanized cereblon mice revealed two distinct therapeutic pathways of immunomodulatory drugs
Gemechu, Y., Millrine, D., Hashimoto, S., Prakash, J., Sanchenkova, K., Metwally, H., Gyanu, P., Kang, S., & Kishimoto, T. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814446115 · Cited by 78
The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia
Li, H., Mar, B. G., Zhang, H., Puram, R. V., Vazquez, F., Weir, B. A., Hahn, W. C., Ebert, B., & Pellman, D. (2017) · Blood · doi:10.1182/blood-2016-05-714493 · Cited by 78
IRF4 in multiple myeloma—Biology, disease and therapeutic target
Agnarelli, A., Chevassut, T. J. T., & Mancini, E. J. (2018) · Leukemia Research · doi:10.1016/j.leukres.2018.07.025 · Cited by 81
Plant ubiquitin ligases as signaling hubs
Shabek, N., & Zheng, N. (2014) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2804 · Cited by 82
Torres, S. E., Gallagher, C. M., Plate, L., Gupta, M., Liem, C. R., Guo, X., Tian, R., Stroud, R. M., Kampmann, M., Weissman, J. S., et al. (2019) · eLife · doi:10.7554/elife.46595 · Cited by 76
“There has been increasing interest in small molecules that induce novel protein-protein interactions with therapeutic potential (de Waal et al., 2016; Han et al., 2017; Krönke et al., 2014; Lu et al., 2014; Krönke et al., 2015; Petzold et al., 2016; Uehara et al., 2017).”
BackgroundRaab, M. S., Thomas, S. K., Ocio, E. M., Guenther, A., Goh, Y. T., Talpaz, M., Hohmann, N., Zhao, S., Xiang, F., Simon, C., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0482-0 · Cited by 82
Hypoxia-inducible KDM3A addiction in multiple myeloma
Ikeda, S., Kitadate, A., Abe, F., Takahashi, N., & Tagawa, H. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017008847 · Cited by 77
Functional Genomics for Cancer Drug Target Discovery
Haley, B., & Roudnicky, F. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.006 · Cited by 79
Ubiquitin proteasome system in immune regulation and therapeutics
Bhat, S. A., Vasi, Z., Adhikari, R., Gudur, A., Ali, A., Jiang, L., Ferguson, R., Liang, D., & Kuchay, S. (2022) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2022.102310 · Cited by 76
Wang, Z., Shaabani, S., Gao, X., Ng, Y. L. D., Sapozhnikova, V., Mertins, P., Krönke, J., & Dömling, A. S. S. (2023) · Nature Communications · doi:10.1038/s41467-023-43614-3 · Cited by 79
RNA-binding protein 39: a promising therapeutic target for cancer
Xu, C., Chen, X., Zhang, X., Zhao, D., Dou, Z., Xie, X., Li, H., Yang, H., Li, Q., Zhang, H., et al. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00598-7 · Cited by 78
Bricelj, A., Ng, Y. L. D., Ferber, D., Kuchta, R. D., Müller, S., Monschke, M., Wagner, K. G., Krönke, J., Sosič, I., Gütschow, M., et al. (2021) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00368 · Cited by 75
Induced protein degradation for therapeutics: past, present, and future
Yoon, H., Rutter, J. C., Li, Y.-D., & Ebert, B. L. (2024) · Journal of Clinical Investigation · doi:10.1172/jci175265 · Cited by 67
Boise, L., Kaufman, J. L., Bahlis, N. J., Lonial, S., & Lee, K. P. (2014) · Blood · doi:10.1182/blood-2014-05-578732 · Cited by 75
Lenalidomide derivatives and proteolysis-targeting chimeras for controlling neosubstrate degradation
Yamanaka, S., Furihata, H., Yanagihara, Y., Taya, A., Nagasaka, T., Usui, M., Nagaoka, K., Shoya, Y., Nishino, K., Yoshida, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40385-9 · Cited by 73
Ubiquitin-specific proximity labeling for the identification of E3 ligase substrates
Huang, H., Lumpkin, R. J., Tsai, R. W., Su, S., Zhao, X., Xiong, Y., Chen, J., Mageed, N., Donovan, K. A., Fischer, E. S., et al. (2024) · Nature Chemical Biology · doi:10.1038/s41589-024-01590-9 · Cited by 76
Chemical Ligand Space of Cereblon
Boichenko, I., Bär, K., Deiss, S., Heim, C., Albrecht, R., Lupas, A. N., Alvarez, B. H., & Hartmann, M. D. (2018) · ACS Omega · doi:10.1021/acsomega.8b00959 · Cited by 74
A novel cereblon modulator for targeted protein degradation
Kim, S. A., Go, A., Jo, S.-H., Park, S. J., Jeon, Y. U., Kim, J. E., Lee, H. K., Park, C. H., Lee, C.-O., Park, S. G., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.01.023 · Cited by 72
Inducing protein-protein interactions with molecular glues
Che, Y., Gilbert, A. M., Shanmugasundaram, V., & Noe, M. C. (2018) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2018.04.046 · Cited by 70
Han, B. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra120.014715 · Cited by 71
Opportunities and challenges of protein-based targeted protein degradation
Shen, F., & Dassama, L. M. K. (2023) · Chemical Science · doi:10.1039/d3sc02361c · Cited by 73
Coleman, K. G., & Crews, C. M. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050430 · Cited by 66
Definition of a small core transcriptional circuit regulated by AML1-ETO
Stengel, K. R., Ellis, J. D., Spielman, C., Bomber, M. L., & Hiebert, S. W. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.12.005 · Cited by 75
Murtaza, N., Cheng, A. A., Brown, C. O., Meka, D. P., Hong, S., Uy, J. A., El-Hajjar, J., Pipko, N., Unda, B. K., Schwanke, B., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111678 · Cited by 65
The Ubiquitin System in Immune Regulation
Park, Y., Jin, H., Aki, D., Lee, J., & Liu, Y. (2014) · Advances in immunology · doi:10.1016/b978-0-12-800147-9.00002-9 · Cited by 77
Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond
Podar, K., & Leleu, X. P. (2021) · Cancers · doi:10.3390/cancers13205154 · Cited by 77
Huh, H. D., Sub, Y., Oh, J., Kim, Y. E., Lee, J. Y., Kim, H.-R., Lee, S., Lee, H., Pak, S., Amos, S. E., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01753-7 · Cited by 72
Dynamic interplay between bone and multiple myeloma: Emerging roles of the osteoblast
Reagan, M. R., Liaw, L., Rosen, C. J., & Ghobrial, I. M. (2015) · Bone · doi:10.1016/j.bone.2015.02.021 · Cited by 66
The emerging role for Cullin 4 family of E3 ligases in tumorigenesis
Cheng, J., Guo, J., North, B. J., Tao, K., Zhou, P., & Wei, W. (2018) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.11.007 · Cited by 74
Evolution of Cereblon-Mediated Protein Degradation as a Therapeutic Modality
Chamberlain, P. P., D’Agostino, L. A., Ellis, J. M., Hansen, J. D., Matyskiela, M. E., McDonald, J. J., Riggs, J. R., & Hamann, L. G. (2019) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.9b00425 · Cited by 68
Monomeric Targeted Protein Degraders
Hanan, E. J., Liang, J., Wang, X., Blake, R. A., Blaquiere, N., & Staben, S. T. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00093 · Cited by 69
Thompson, J. W., Nagel, J., Hoving, S., Gerrits, B., Bauer, A., Thomas, J. R., Kirschner, M. W., Schirle, M., & Luchansky, S. J. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.573352 · Cited by 71
Zhang, Z., Tong, J., Tang, X., Juan, J., Cao, B., Hurren, R., Chen, G., Taylor, P. P., Xu, X., Shi, C.-X., et al. (2016) · Blood · doi:10.1182/blood-2015-07-658203 · Cited by 69
The making of a lymphocyte: the choice among disparate cell fates and the IKAROS enigma
Georgopoulos, K. (2017) · Genes & Development · doi:10.1101/gad.297002.117 · Cited by 72
Emerging drug development technologies targeting ubiquitination for cancer therapeutics
Veggiani, G., Gerpe, M. C. R., Sidhu, S. S., & Zhang, W. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.03.003 · Cited by 63
Ng, Y. L. D., Ramberger, E., Bohl, S., Dolnik, A., Steinebach, C., Conrad, T., Müller, S., Popp, O., Kull, M., Haji, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28515-1 · Cited by 71
Targeted protein posttranslational modifications by chemically induced proximity for cancer therapy
Peng, Y., Liu, J., Inuzuka, H., & Wei, W. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104572 · Cited by 71
Ichiyama, K., Long, J., Kobayashi, Y., Horita, Y., Kinoshita, T., Nakamura, Y., Kominami, C., Georgopoulos, K., & Sakaguchi, S. (2024) · Immunity · doi:10.1016/j.immuni.2024.07.010 · Cited by 69
Protein Engineering in the Ubiquitin System: Tools for Discovery and Beyond
Zhao, B., Tsai, Y. C., Jin, B., Wang, B., Wang, Y., Zhou, H., Carpenter, T., Weissman, A. M., & Yin, J. (2020) · Pharmacological Reviews · doi:10.1124/pr.118.015651 · Cited by 70
Soluble SLAMF7 promotes the growth of myeloma cells via homophilic interaction with surface SLAMF7
Kikuchi, J., Hori, M., Iha, H., Toyama‐Sorimachi, N., Hagiwara, S., Kuroda, Y., Koyama, D., Izumi, T., Yasui, H., Suzuki, A., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0525-6 · Cited by 67
Bifunctional Small‐Molecule Ligands of K‐Ras Induce Its Association with Immunophilin Proteins
Zhang, Z., & Shokat, K. M. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201910124 · Cited by 66
Franssen, L. E., Nijhof, I. S., Couto, S., Levin, M.-D., Bos, G. M. J., Broijl, A., Klein, S. K., Ren, Y., Wang, M., Koene, H. R., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.186601 · Cited by 66
“Prior lines of therapy, median (range) 3 (1-6)”
BackgroundImmunotherapy in myeloma: how far have we come?
Franssen, L. E., Mutis, T., Lokhorst, H. M., & van de Donk, N. W. C. J. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620718822660 · Cited by 66
Hideshima, T., Cottini, F., Ohguchi, H., Jakubikova, J., Gorgun, G., Mimura, N., Tai, Y.-T., Munshi, N. C., Richardson, P. G., & Anderson, K. C. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.38 · Cited by 64
FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor
Ran, L., Chen, Y., Sher, J. J., Wong, E. W. P., Murphy, D. A., Zhang, J. Q., Li, D., Denız, K., Sirota, I., Cao, Z., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0468 · Cited by 70
Peptidic degron for IMiD-induced degradation of heterologous proteins
Koduri, V., McBrayer, S. K., Liberzon, E., Wang, A. C., Briggs, K. J., Cho, H., & Kaelin, W. G. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818109116 · Cited by 64
Self-citationSperling, A. S., Burgess, M., Keshishian, H., Gasser, J. A., Bhatt, S., Jan, M., Słabicki, M., Sellar, R. S., Fink, E. C., Miller, P. G., et al. (2019) · Blood · doi:10.1182/blood.2019000789 · Cited by 64
A MedChem toolbox for cereblon-directed PROTACs
Steinebach, C., Sosič, I., Lindner, S., Bricelj, A., Kohl, F., Ng, Y. L. D., Monschke, M., Wagner, K. G., Krönke, J., & Gütschow, M. (2019) · MedChemComm · doi:10.1039/c9md00185a · Cited by 60
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
Zhou, N., Gutierrez-Uzquiza, A., Zheng, X. Y., Chang, R., Vogl, D. T., Garfall, A. L., Bernabei, L., Saraf, A., Florens, L., Washburn, M. P., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0403-2 · Cited by 61
Emerging Therapeutic Strategies to Overcome Drug Resistance in Multiple Myeloma
Davis, L. N., & Sherbenou, D. W. (2021) · Cancers · doi:10.3390/cancers13071686 · Cited by 67
Development of PDE6D and CK1α Degraders through Chemical Derivatization of FPFT-2216
Teng, M., Lu, W., Donovan, K. A., Sun, J., Krupnick, N. M., Nowak, R. P., Li, Y.-D., Sperling, A. S., Zhang, T., Ebert, B. L., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01832 · Cited by 63
Teng, M., & Gray, N. S. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.06.020 · Cited by 66
How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
Kater, A. P., Tonino, S. H., Egle, A., & Ramsay, A. G. (2014) · Blood · doi:10.1182/blood-2014-05-578286 · Cited by 68
Repurposing old drugs as new inhibitors of the ubiquitin-proteasome pathway for cancer treatment
Yang, H., Chen, X., Li, K., Cheaito, H. A., Yang, Q., Wu, G., Liu, J., & Dou, Q. P. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.013 · Cited by 65
Ramachandran, S., & Ciulli, A. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2020.10.009 · Cited by 60
Huang, S.-Y., Lin, C.-W., Lin, H.-H., Yao, M., Tang, J.-L., Wu, S.-J., Chen, Y.-C., Lu, H.-Y., Hou, H.-A., Chen, C.-Y., et al. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2063-7 · Cited by 62
“In primary human T cells treated with lenalidomide, both IKZF1 and IKZF3 protein levels decreased markedly, suggesting that induction of IL-2 is mediated by derepression of the IL-2 gene expression by depletion of IKZF1 and IKZF3 [10, 11].”
BackgroundInfluentialChemoproteomic-enabled phenotypic screening
Conway, L. P., Li, W., & Parker, C. G. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.01.012 · Cited by 63
Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic
Li, D., Yu, X., Kottur, J., Gong, W., Zhang, Z., Storey, A. J., Tsai, Y.-H., Uryu, H., Shen, Y., Byrum, S. D., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02340-8 · Cited by 57
Induced proximity-based therapeutic modalities
King, E. A., Meyers, M., & Nomura, D. K. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01316-z · Cited by 73
Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathways
Hideshima, T., Ogiya, D., Liu, J., Harada, T., Kurata, K., Bae, J. E., Massefski, W. W., & Anderson, K. C. (2020) · Leukemia · doi:10.1038/s41375-020-0809-x · Cited by 68
Chen, Y.-A., Peng, Y.-J., Hu, M.-C., Huang, J.-J., Chien, Y.-C., Wu, J.-T., Chen, T.-Y., & Tang, C.-Y. (2015) · Scientific Reports · doi:10.1038/srep10667 · Cited by 61
The Ikaros family of zinc-finger proteins
Fan, Y., & Lu, D. (2016) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2016.06.002 · Cited by 61
Ito, T., Yamaguchi, Y., & Handa, H. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2021.04.012 · Cited by 58
Aubrey, B. J., Cutler, J. A., Bourgeois, W., Donovan, K. A., Gu, S. S., Hatton, C., Perlee, S. C., Perner, F., Rahnamoun, H., Theall, A. C. P., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00366-1 · Cited by 64
Thomas, J. E., Wang, M., Jiang, W., Wang, M., Wang, L., Wen, B., Sun, D., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00492 · Cited by 63
Screening for molecular glues – Challenges and opportunities
Holdgate, G. A., Bardelle, C., Berry, S. K., Lanne, A., & Cuomo, M. E. (2023) · SLAS DISCOVERY · doi:10.1016/j.slasd.2023.12.008 · Cited by 67
Targeting ubiquitination in disease and therapy
Yang, X., Lan, T., Zhang, B., Tao, X., Qi, W., Xie, K., Cai, Y., Liu, C., Han, J., & Wu, H. M. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02392-8 · Cited by 67
Rychak, E., Mendy, D., Shi, T., Ning, Y., Leisten, J., Lu, L., Miller, K., Narla, R. K., Orlowski, R. Z., Raymon, H. K., et al. (2016) · British Journal of Haematology · doi:10.1111/bjh.13905 · Cited by 60
A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma
Chari, A., Cho, H. J., Dhadwal, A., Morgan, G., La, L., Zarychta, K., Catamero, D., Florendo, E., Stevens, N., Verina, D., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017007427 · Cited by 62
Epidemiology, genetics and treatment of multiple myeloma and precursor diseases
Hemminki, K., Försti, A., Houlston, R. S., & Sud, A. (2021) · International Journal of Cancer · doi:10.1002/ijc.33762 · Cited by 70
Molecular glue concept solidifies
Baek, K., & Schulman, B. A. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0414-3 · Cited by 65
Heider, M., Eichner, R., Stroh, J., Morath, V., Kuisl, A., Zecha, J., Lawatscheck, J., Baek, K., Garz, A.-K., Rudelius, M., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2020.12.046 · Cited by 62
Karagiannakos, A., Adamaki, M., Tsintarakis, A., Vojtěšek, B., Fåhræus, R., Zoumpourlis, V. C., & Karakostis, K. (2022) · Cancers · doi:10.3390/cancers14030664 · Cited by 62
Update on the role of lenalidomide in patients with multiple myeloma
Holstein, S. A., Suman, V. J., & McCarthy, P. L. (2018) · Therapeutic Advances in Hematology · doi:10.1177/2040620718775629 · Cited by 61
Overcoming the Immunosuppressive Tumor Microenvironment in Multiple Myeloma
Uckun, F. M. (2021) · Cancers · doi:10.3390/cancers13092018 · Cited by 61
The Multiple Myeloma Drug Pipeline—2018: A Review of Small Molecules and Their Therapeutic Targets
Abramson, H. N. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.06.015 · Cited by 62
Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Salerno, A., Seghetti, F., Caciolla, J., Uliassi, E., Testi, E., Guardigni, M., Roberti, M., Milelli, A., & Bolognesi, M. L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00302 · Cited by 59
Steinebach, C., Bricelj, A., Murgai, A., Sosič, I., Bischof, L., Ng, Y. L. D., Heim, C., Maiwald, S. A., Proj, M., Voget, R., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00851 · Cited by 60
Hideshima, T., Cottini, F., Nozawa, Y., Seo, H., Ohguchi, H., Samur, M., Cirstea, D. D., Mimura, N., Iwasawa, Y., Richardson, P. G. G., et al. (2017) · Blood · doi:10.1182/blood-2016-09-738500 · Cited by 60
Rapid synthesis of pomalidomide-conjugates for the development of protein degrader libraries
Brownsey, D. K., Rowley, B. C., Gorobets, E., Gelfand, B. S., & Derksen, D. J. (2021) · Chemical Science · doi:10.1039/d0sc05442a · Cited by 62
Nishiguchi, G., Mascibroda, L. G., Young, S. M., Caine, E. A., Abdelhamed, S., Kooijman, J. J., Miller, D. J., Das, S., McGowan, K., Mayasundari, A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-44698-1 · Cited by 57
Geiger, T. M., Schäfer, S. C., Dreizler, J. K., Walz, M., & Hausch, F. (2022) · Current Research in Chemical Biology · doi:10.1016/j.crchbi.2021.100018 · Cited by 52
Luo, X., Archibeque, I., Dellamaggiore, K., Smither, K., Homann, O. R., Lipford, J. R., & Mohl, D. A. (2022) · iScience · doi:10.1016/j.isci.2022.103985 · Cited by 60
PAX3-FOXO1: Zooming in on an “undruggable” target
Wachtel, M., & Schäfer, B. W. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.006 · Cited by 59
Protein-slaying drugs could be the next blockbuster therapies
Scudellari, M. (2019) · Nature · doi:10.1038/d41586-019-00879-3 · Cited by 60
Profiling the Landscape of Drug Resistance Mutations in Neosubstrates to Molecular Glue Degraders
Gosavi, P. M., Ngan, K. C., Yeo, M. J. R., Su, C., Li, J., Lue, N. Z., Hoenig, S. M., & Liau, B. B. (2022) · ACS Central Science · doi:10.1021/acscentsci.1c01603 · Cited by 56
Dual IKZF2 and CK1α degrader targets acute myeloid leukemia cells
Park, S.-M., Miyamoto, D. K., Han, G. Y. Q., Chan, M., Curnutt, N. M., Tran, N. L., Velleca, A., Kim, J. H., Schurer, A., Chang, K., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.010 · Cited by 56
Liu, Y., Huang, X., He, X., Zhou, Y., Jiang, X., Chen‐Kiang, S., Jaffrey, S. R., & Xu, G. (2015) · The FASEB Journal · doi:10.1096/fj.15-274050 · Cited by 57
Metadata
- Authors
- Lu, G., Middleton, R. E., Sun, H., Naniong, M., Ott, C. J., Mitsiades, C. S., Wong, K.-K., Bradner, J. E., & Kaelin, W. G.
- Affiliations
- Dana-Farber Cancer Institute (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Kaelin, William G.
- ORCID
- Venue
- Science
- Published
- 2014-01-17
- Volume
- 343
- Issue
- 6168
- Pages
- 305-309
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC4070318
- OpenAlex
- W2068412287
- Semantic Scholar
- 78bec298ec2a26703ac77b2d1a6e38c4778689df
- Cited by
- 1,583
- References
- 35
- Citations by year
- 2026: 113 · 2025: 123 · 2024: 152 · 2023: 136 · 2022: 149 · 2021: 179 · 2020: 167 · 2019: 111 · 2018: 120 · 2017: 93 · 2016: 88 · 2015: 85 · 2014: 63
- FWCI
- 35.56
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (R01CA068490, R01CA076120)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- lenalidomide, cereblon, IKZF1, IKZF3, multiple myeloma, ubiquitin ligase, proteasomal degradation, teratogenicity, zebrafish, anticancer mechanism
- MeSH terms
- Lenalidomide, Antineoplastic Agents, Humans, Multiple Myeloma, Peptide Hydrolases, Teratogens, Thalidomide, Ubiquitin-Protein Ligases, Cell Line, Tumor, Adaptor Proteins, Signal Transducing, Ikaros Transcription Factor, HEK293 Cells, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.